N@N

Douglas Tsao Reiterated (APLS) at Strong Buy and Held Target at $87 on, Feb 23rd, 2023

Douglas Tsao of HC Wainwright & Co., Reiterated "Apellis Pharmaceuticals, Inc." (APLS) at Strong Buy and Held Target at $87 on, Feb 23rd, 2023.

Douglas has made no other calls on APLS in the last 4 months.

There are 9 other peers that have a rating on APLS. Out of the 9 peers that are also analyzing APLS, 3 agree with Douglas's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Derek Archila of "Wells Fargo" Downgraded from Buy to Hold and Held Target at $58 on, Tuesday, January 3rd, 2023
• Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $40 on, Thursday, November 10th, 2022
• Tiago Fauth of "Credit Suisse" Maintained at Hold with Decreased Target to $43 on, Tuesday, November 8th, 2022

These are the ratings of the 6 analyists that currently disagree with Douglas

---

• Joseph Stringer of "Needham" Maintained at Strong Buy and Held Target at $80 on, Wednesday, February 22nd, 2023
• Steven Seedhouse of "Raymond James" Maintained at Strong Buy with Increased Target to $139 on, Wednesday, February 22nd, 2023
• Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Increased Target to $91 on, Tuesday, February 21st, 2023
• Annabel Samimy of "Stifel" Maintained at Strong Buy with Increased Target to $75 on, Tuesday, February 21st, 2023
• Colleen Kusy of "Baird" Maintained at Buy with Increased Target to $105 on, Tuesday, February 21st, 2023
• Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $79 on, Tuesday, November 15th, 2022

Contributing Sources

---